This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Bupropion Clarification

Richard S. Kent

Published: March 31, 1999

Article Abstract

Letter to the Editor

Sir: The recent Glaxo Wellcome-sponsored supplement to the Journal entitled "Beyond SSRIs" provides clinicians with useful information regarding the treatment of depression and discusses our bupropion product. I would like to provide clarification on some aspects of the supplement relating to bupropion.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 60

Quick Links: